REVIEW article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1608338
This article is part of the Research TopicAdvances in Innate Immune Cells in chronic non-transmissible diseases: From Sensing to Effector Mechanisms in Inflammatory DiseasesView all 4 articles
The Myeloid Switch: Immune Drivers in Atopic Dermatitis -Roles in Pathogenesis and Emerging Therapeutic Targeting
Provisionally accepted- 1Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland
- 2Christine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland
- 3ITMP, University of Bern, Bern, Switzerland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide, significantly impairing patients' quality of life. It is characterized by recurrent eczematous lesions, intense pruritus, and disruption of the epidermal barrier. The pathogenesis of AD is multifactorial and involves complex interactions between genetic predisposition, environmental triggers, skin barrier defects, microbial dysbiosis, and immune dysregulation. While much of the research in recent decades has focused on the type 2 helper T cell (Th2)-driven adaptive immune responses that dominate the acute phase of the disease, the role of innate immunity-particularly that of myeloid cells-has emerged as a crucial and underrated component in disease pathogenesis and progression.This review highlights recent findings on the role of myeloid cells in the initiation, maintenance, and amplification of inflammation in AD. Myeloid cells respond to a wide range of environmental and tissue-derived triggers, including cytokines, alarmins, and microbial products. Upon activation, they contribute to the inflammatory milieu by producing chemokines and cytokines, presenting antigens, and recruiting other immune cells to the skin. Importantly, myeloid cells not only shape the local immune landscape but also engage in crosstalk with keratinocytes and adaptive immune cells, thereby reinforcing chronic inflammation.In addition, the review outlines emerging therapeutic strategies aimed at modulating myeloid cell function or selectively targeting pro-inflammatory subsets. These approaches offer promising avenues that complement existing Th2-centered therapies, addressing disease mechanisms beyond the adaptive immune response. A deeper understanding of the diverse and dynamic roles of myeloid cells in AD may thus support the development of more comprehensive and personalized treatment strategies for long-term disease control.
Keywords: atopic dermatitis, Myeloid Cells, Dendritic Cells, immunology, inflammatory disease, therapeutic targets , immune drivers
Received: 08 Apr 2025; Accepted: 04 Jun 2025.
Copyright: © 2025 Kupschke and Schenk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mirjam Schenk, ITMP, University of Bern, Bern, Switzerland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.